To confirm that the PARD3 overexpression-induced CD133+ cell population acquired tumour-initiating properties, we used an in vitro limiting dilution assay to measure the sphere-forming ability of PARD3-overexpressing CD133+ Hepa1-6 cells. The gene discussed is PROM1; the disease is neoplasm.